The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
Authors
Keywords
-
Journal
GUT
Volume 64, Issue 10, Pages 1539-1545
Publisher
BMJ
Online
2014-10-22
DOI
10.1136/gutjnl-2014-307883
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
- (2014) B. G. Levesque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
- (2014) Filip Baert et al. Clinical Gastroenterology and Hepatology
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- Tailoring anti-TNF therapy in IBD: drug levels and disease activity
- (2014) Shomron Ben-Horin et al. Nature Reviews Gastroenterology & Hepatology
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects
- (2013) C L M Krieckaert et al. ANNALS OF THE RHEUMATIC DISEASES
- A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
- (2013) Fernando S. Velayos et al. Clinical Gastroenterology and Hepatology
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2013) Xavier Roblin et al. Clinical Gastroenterology and Hepatology
- Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
- (2013) Brian G. Feagan et al. GASTROENTEROLOGY
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
- (2013) Bella Ungar et al. GUT
- Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
- (2013) Laurent Peyrin-Biroulet et al. GUT
- Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease
- (2013) Stephane Paul et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohnʼs Disease
- (2013) Casper Steenholdt et al. THERAPEUTIC DRUG MONITORING
- Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
- (2012) N. Vande Casteele et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
- (2012) Kavinderjit S Nanda et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
- (2012) Casper Steenholdt et al. INFLAMMATORY BOWEL DISEASES
- Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies
- (2012) Ren Mao et al. INFLAMMATORY BOWEL DISEASES
- OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial
- (2012) N. Vande Casteele et al. Journal of Crohns & Colitis
- Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
- (2012) Martin Bortlik et al. Journal of Crohns & Colitis
- Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
- (2012) Shui-Long Wang et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease
- (2011) Matthias Jürgens et al. Clinical Gastroenterology and Hepatology
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Monitoring functional serum antitumor necrosis factor antibody level in Crohnʼs disease patients who maintained and those who lost response to anti-TNF
- (2010) Akihiro Yamada et al. INFLAMMATORY BOWEL DISEASES
- Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
- (2010) Casper Steenholdt et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started